Belhaven Biopharma | WebDisclosure

BRIEF

published on 07/09/2024 at 17:05, 5 months 11 days ago

Belhaven Biopharma Study Shows Promising Results for Nasal Epinephrine Delivery

Belhaven Biopharma Nasdepi Anaphylaxis Treatment Medical Research Nasal Epinephrine
BRIEF

published on 07/09/2024 at 17:05, 5 months 11 days ago

L'étude Belhaven Biopharma montre des résultats prometteurs pour l'administration nasale d'épinéphrine

Belhaven Biopharma Nasdepi Recherche Médicale Traitement De L'anaphylaxie Épinéphrine Nasale
PRESS RELEASE

published on 07/09/2024 at 17:00, 5 months 11 days ago

New Canine Study From Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution
Belhaven Biopharma presents promising results of Nasdepi Canine Study at Respiratory Drug Delivery 2024, indicating faster & effective treatment for anaphylaxis. Intranasal dry powder epinephrine offers breakthrough prospects in emergency care for severe allergies

Belhaven Biopharma Anaphylaxis Treatment Nasdepi Canine Study Dry Powder Nasal Solution Respiratory Drug Delivery 2024
PRESS RELEASE

published on 02/08/2024 at 18:30, 10 months 12 days ago

Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
Belhaven Biopharma shares positive results from Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device for treating anaphylaxis. Successful investor round and Series A financing on the horizon

Phase 1 Clinical Trial Series A Financing Belhaven Biopharma Nasdepi Anaphylaxis Treatment
PRESS RELEASE

published on 11/28/2023 at 19:30, 1 year ago

Belhaven Biopharma Achieves Significant Milestones in Advancing Nasdepi - a Revolutionary Nasal Dry Powder Epinephrine Product

Published on 12/21/2024 at 01:30, 14 hours 31 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 14 hours 31 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 15 hours 56 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 16 hours 1 minute ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 16 hours 31 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 15 hours 10 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 15 hours 16 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 20 hours 51 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 21 hours 5 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 22 hours 1 minute ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 3 hours 43 minutes ago

AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 3 hours 43 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 22 hours 1 minute ago

Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 22 hours 1 minute ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 22 hours 6 minutes ago

Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024

View all LES ECHOS COMFI WIRE

News